{{Rsnum
|rsid=822395
|Gene=ADIPOQ
|Chromosome=3
|position=186849018
|Orientation=plus
|GMAF=0.2938
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ADIPOQ
}}{{PMID Auto
|PMID=21397927
|Title=Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk
|OA=1
}}

{{PMID Auto
|PMID=21619462
|Title=The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer
}}

{{PMID Auto
|PMID=21637408
|Title=A lack of association between adiponectin polymorphisms and coronary artery disease in a Chinese population
|OA=1
}}

{{PMID|17712123}} Single nucleotide polymorphisms at the adiponectin locus and risk of coronary heart disease in men and women.

{{PMID|18451143|OA=1
}} Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk.

{{PMID|18523726|OA=1
}} Adiponectin gene ADIPOQ SNP associations with serum adiponectin in two female populations and effects of SNPs on promoter activity.

{{PMID|18827209|OA=1
}} Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.

{{PMID|19912668|OA=1
}} Design and evaluation of a treatment programme for Spanish adolescents with overweight and obesity. The EVASYON Study.

{{PMID|22386722}} Association of ADIPOQ gene polymorphisms and coronary artery disease risk: a meta-analysis based on 12 465 subjects.

{{PMID Auto
|PMID=23200411
|Title=ADIPOQ gene polymorphisms and cancer risk: A meta-analysis
}}

{{PMID Auto
|PMID=23351195
|Title=A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome
|OA=1
}}

{{PMID Auto
|PMID=23740135
|Title=The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk
}}

{{PMID Auto
|PMID=23225349
|Title=Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}